Guerbet Stock Rises by 5.72%: +18% in One Week After Months of Decline
On Tuesday midday, Guerbet's stock price increased by 5.72%, trading at 10.54 euros after closing at 9.97 euros the previous day. This surge comes within a context of a notable weekly rebound, with an 18% increase over seven days, although the medical imaging contrast agent specialist has seen a significant decline over three months (-26.5%) and over one year (-47.95%).
Recovery Movement After Weeks of Sharp Decline
Guerbet's progress this Tuesday is part of a recovery movement following several weeks of sharp decline. The stock is now trading above its 20-day moving average, which is at 10.29 euros, a breakthrough indicating a short-term momentum gain. However, the price remains far from its 50-day and 200-day averages, at 12.33 and 16.33 euros respectively, highlighting the significant undervaluation accumulated in recent months.
The Relative Strength Index (RSI), which measures the speed of upward and downward movements, is at 41: a moderate level indicating that the stock is not in an overbought zone despite the recent rebound. The technical support threshold identified at 8.20 euros was not tested during the last downward phase, while the most relevant resistance lies at 13.72 euros, which is more than 30% above the current price.
Crucial Weeks Ahead for Guerbet Fundamentally
The upcoming weeks are crucial for Guerbet fundamentally. The publication of the first quarter 2026 revenue is expected on April 23, followed by the annual general meeting of shareholders scheduled for May 22. These events will assess the commercial trajectory of the group, as the stock has lost nearly half of its value over the past year.
The movement of the day occurs in a mixed market environment. The CAC 40 is up by 0.73% during the session, at 7,828.88 points, while the SBF 120 gains 0.77%. However, overall volatility remains high, with the VIX at 31.05 points at the close of March 27, indicating significant market stress. Guerbet's beta, at 0.72, shows less sensitivity to general market fluctuations, which partly mitigates the direct influence of the macroeconomic context on the stock.
